DURHAM – Johnson & Johnson is cutting jobs nationwide. Just how many is unclear, but sources have told WRAL TechWire that multiple teams at the pharmaceutical company have experienced layoffs. Cut also reportedly are on the way at J&J owned Janssen Biotech.
The company has not responded to multiple inquiries regarding the layoffs.
It is hiring in the Triangle for at least one role with Janssen, a subsidiary of Johnson & Johnson.
FiercePharma reported Friday that cuts are coming in the Janssen group. Executives told a “nervous group of employees” that “an overhaul of operations for the infectious diseases and vaccine groups” is coming with what it called “sweeping layoffs.”
According to LinkedIn, there are about 200 workers in the Triangle who have current roles at Johnson & Johnson or a subsidiary company.
The global pharmaceutical company reported quarterly and annual earnings in January.
“Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and CEO of Johnson & Johnson in a statement released with the firm’s earnings report. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value.”
For sales, the company reported full-year revenues of $94.9 billion and noted in the statement that was “primarily driven by strong commercial execution partially offset by unfavorable foreign exchange.” That result represented a 1.3% growth for the year, according to the company.
In October, J&J announced plans to lay off 64 workers in New York, according to FiercePharma.